Novel treatment strategies for aggressive non-Hodgkin's lymphoma

被引：5
|
作者：
Fayad, L [1 ]
Younes, A [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2006年 / 7卷 / 06期
关键词：
Akt; aurora; BAFF; CD40; Hsp-90; HDAC; mTOR; PLK; TRAIL;
D O I：
10.1517/14656566.7.6.733
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The World Health Organization has included different types of lymphoma under the aggressive category. In the US, diffuse large B-cell lymphoma is the most common aggressive lymphoma and accounts for > 30% of the 55,000 new cases diagnosed annually. Recent advances in the knowledge of the molecular biology have provided an increased understanding of the heterogeneity of non-Hodgkin's lymphoma. New treatments, especially those with the use of monoclonal antibodies, are improving both the survival and the response rate.
引用
收藏
页码：733 / 748
页数：16
相关论文
共 50 条
  • [31] Prognostic factors in localized aggressive non-Hodgkin's lymphoma
    Alici, S
    Bavbek, SE
    Kaytan, E
    Eralp, Y
    Onat, H
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (01): : 1 - 5
  • [32] TREATMENT STRATEGIES IN CHILDHOOD MALIGNANT NON-HODGKIN LYMPHOMA
    GADNER, H
    MULLERWEIHRICH, S
    RIEHM, H
    ONKOLOGIE, 1986, 9 (02): : 126 - 130
  • [33] Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
    Stiff, Patrick J.
    Unger, Joseph M.
    Cook, James R.
    Constine, Louis S.
    Couban, Stephen
    Stewart, Douglas A.
    Shea, Thomas C.
    Porcu, Pierluigi
    Winter, Jane N.
    Kahl, Brad S.
    Miller, Thomas P.
    Tubbs, Raymond R.
    Marcellus, Deborah
    Friedberg, Jonathan W.
    Barton, Kevin P.
    Mills, Glenn M.
    LeBlanc, Michael
    Rimsza, Lisa M.
    Forman, Stephen J.
    Fisher, Richard I.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (18): : 1681 - 1690
  • [34] Therapy for stage I aggressive non-Hodgkin's lymphoma
    Kluin-Nelemans, HC
    CROATIAN MEDICAL JOURNAL, 2002, 43 (05) : 546 - 549
  • [35] Current guidelines for the management of aggressive non-Hodgkin's lymphoma
    Martelli, M
    DeSanctis, V
    Avvisati, G
    Mandelli, F
    DRUGS, 1997, 53 (06) : 957 - 972
  • [36] Relative risk of cardiovascular disease after treatment for aggressive non-Hodgkin's lymphoma
    Moser, EC
    Noordijk, EM
    van Leeuwen, FE
    le Cessie, S
    Baars, JW
    Thomas, J
    Carde, P
    van Glabbeke, M
    Meerwaldt, JH
    Kluin-Nelemans, JC
    BLOOD, 2005, 106 (11) : 794A - 794A
  • [37] Non-hodgkin's lymphoma in the elderly - Part 2: Treatment of diffuse aggressive lymphomas
    Morrison, Vicki A.
    ONCOLOGY-NEW YORK, 2007, 21 (10): : 1191 - 1198
  • [38] Treatment of aggressive non-Hodgkin's lymphoma in adults - Are we doing any better?
    Hagberg, H
    Kimby, E
    MEDICAL ONCOLOGY, 1996, 13 (04): : 185 - 194
  • [39] Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma
    Fosså, A
    Santoro, A
    Hiddemann, W
    Truemper, L
    Niederle, N
    Buksmaui, S
    Bonadonna, G
    Seeber, S
    Nowrousian, MR
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) : 3786 - 3792
  • [40] Outcome of Hodgkin's lymphoma and aggressive non-Hodgkin lymphoma patients refractory to salvage chemotherapy
    Castagna, L.
    Bramanti, S.
    Balzarotti, M.
    Giordano, L.
    Michieli, M.
    Anastasia, A.
    Magagnoli, M.
    Sarina, B.
    Todisco, E.
    Mazza, R.
    Nozza, A.
    Ibatici, A.
    Santoro, A.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S249 - S249
12345